Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

DON in Pediatric Cerebral Malaria

A legfontosabb adatok

Ki végzi
Douglas Postels, MD, MS
Hol
Malawi2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
152 fő, tervezett
Kezdés
2022. aug. 16.
Várható befejezés
2028. nov. 30.
A vizsgálat típusa
Beavatkozással járó, 13 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • 6-diazo-5-oxo-L-norleucine (DON)
  • Placebo
A regiszteradat frissítve
2026. október 23.

Ki vehet részt

Életkor
12 hónap – 14 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 41 feltétel megnézéseKevesebb

Ki vehet részt

  • For Healthy Adults (Part 1):
  • 18 years and older
  • Informed consent obtained and ICF signed
  • Temperature ≤ 37.5 °C
  • BMI 18.5-25 kg/m2
  • Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
  • Hemoglobin ≥ 7 g/dL or hematocrit/ packed-cell volume (PCV) ≥ 20%
  • Thick or thin blood smear negative for asexual forms of P. falciparum
  • Negative pregnancy test for persons of child-bearing potential; For Adults with Uncomplicated Malaria (Part 1):
  • 18 years and older
  • Informed consent obtained and ICF signed
  • Temperature ≥ 38 °C or history of fever in the past 24 hours
  • Thick or thin blood smear positive for asexual forms of P. falciparum (parasite count and speciation documented)
  • Hemoglobin ≥ 7 g/dL or hematocrit/ PCV ≥ 20%
  • BMI 18.5-25 kg/m2
  • Creatinine ≤ 110 mmol/L (≤ 1.2 mg/dL; males) or ≤ 90 mmol/L (≤ 1.0 mg/dL; females)
  • Glasgow coma score of 15
  • Respiratory rate ≤ 20 breaths/ minute
  • Oxygen saturation ≥ 90% on room air
  • Negative pregnancy test for person of child-bearing potential; For Children with Cerebral Malaria (Part 2):
  • Age 12 months-14 years old
  • Informed consent obtained and ICF signed by parent or guardian
  • Temperature ≥ 38 °C or history of fever in the last 24 hours
  • Thick or thin blood smear positive for asexual forms of P. falciparum
  • Blantyre coma score ≤ 2
  • No other explanation for coma by history or physical exam
  • Hematocrit or PCV ≥ 18%
  • Negative pregnancy test for persons of child-bearing potential
  • Creatinine ≤ 1.5 mg/dL
  • Aspartate aminotransferase (AST) < 280 IU/L
  • Alanine aminotransferase (ALT) < 195 IU/L

Ki nem vehet részt

  • Pregnancy or lactation (participants of child-bearing potential ages 9-59 years will undergo pregnancy testing prior to administration of the intervention)
  • Currently taking highly active antiretroviral therapy (HAART)
  • Currently taking anti-tuberculosis medications
  • Have taken a CYP3A4 inhibitor within 7 days of enrollment
  • Allergy to ondansetron or ceftriaxone; Additional Exclusion Criteria for Children with Cerebral Malaria (Part 2):
  • Cloudy cerebrospinal fluid (indicative of a probable bacterial central nervous system infection)
  • Allergy to ondansetron or ceftriaxone
  • Participants attempting to become pregnant
  • Severe malnutrition (>3 standard deviations below the mean weight for height and/ or mid-upper arm circumference (MUAC) ≤11.5 cm
  • Coma for > 72 hours

Ez a vizsgálat jelenleg itt érhető el: Malawi.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to evaluate the safety of a single intravenous dose of DON in healthy adults, adults with uncomplicated malaria, and children 12 months-14 years old with clinically defined Cerebral Malaria. The main objectives are:

A teljes eredeti leírásKevesebb

* Evaluate the safety of a single intravenous dose of DON in healthy adults and adults with uncomplicated malaria ( Part 1) * Determine the safety of a single dose of DON in children 12 months-14 years old with World Health Organization (WHO) clinically defined CM (Part 2 :Cohort 1-4) * Determine the pharmacokinetic (PK) profile of a single dose of DON in healthy adults, adults with uncomplicated malaria and children with CM (Part 1, and Cohorts 1-4 of Part 2) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with improved intracerebral blood flow dynamics on transcranial doppler (TCD) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with CM is associated with a reduction in brain volume score on magnetic resonance imaging (MRI) (Part 2 :Cohort 1-4) * Determine if administration of a single intravenous dose of DON as an adjunctive therapy in children with cerebral malaria is associated with changes in electroencephalogram (EEG) pattern (Part 2 :Cohort 1-4) * Exploratory: Explore the metabolic mechanisms of action of adjunctive DON in children with CM

Healthy adult participants will receive:

* anti-emetic ondansetron * one dose of DON

Adults with uncomplicated malaria will receive:

* anti-emetic ondansetron * one dose of DON * artemisinin-combination therapies per Malawi Ministry of Health guidelines

Pediatric participants will receive:

* one dose of DON * anti-emetic ondansetron and per Malawi Ministry of Health guidelines: * enteral lumefantrine-artemether therapy, and * artesunate therapy

A vizsgálat 13 csoportja

  • Dose escalation in healthy Malawian adults - 0.1 mg/kg IV DONA vizsgált kezelés

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 1.0 mg/kg IV DONA vizsgált kezelés

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 5.0 mg/kg IV DONA vizsgált kezelés

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in healthy Malawian adults - 10.0 mg/kg IV DONA vizsgált kezelés

    The first 10 healthy adult participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 0.1 mg/kg IV DONA vizsgált kezelés

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 1.0 mg/kg IV DONA vizsgált kezelés

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 5.0 mg/kg IV DONA vizsgált kezelés

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian adults with uncomplicated malaria - 10.0 mg/kg IV DONA vizsgált kezelés

    The first 10 adults with uncomplicated malaria participants enrolled will receive a single 0.1 mg/kg intravenous (IV) DON. If this dose is proven safe, in each subsequent group of 10, the dose will be increased to 1.0 mg/kg IV DON and then 5.0 mg/kg IV DON, and then the final group will receive 10.0 mg/kg IV DON.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 1A vizsgált kezelés

    After adult doses are shown to be safe. Of the first 6 children with cerebral malaria enrolled, 4 will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 mg/kg IV DON - Cohort 2A vizsgált kezelés

    10 participants will receive 0.1 mg/kg IV DON, and 2 will receive placebo.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 1.0 mg/kg IV DON - Cohort 3A vizsgált kezelés

    14 participants will receive 1.0 mg/kg IV DON, and 4 will receive placebo.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - 0.1 or 1.0 mg/kg IV DON - Cohort 4A vizsgált kezelés

    36 participants will receive 0.1 mg/kg IV DON (n=12) or 1.0 mg/kg IV DON (n=12), and 12 will receive placebo.

    Kezelés: 6-diazo-5-oxo-L-norleucine (DON)

  • Dose escalation in Malawian children with cerebral malaria - placeboPlacebo, összehasonlításként

    Cohort 1 will dose 2 participants to receive placebo Cohort 2 will dose 2 participants to receive placebo Cohort 3 will dose 4 participants to receive placebo Cohort 4 will dose 12 participants to receive placebo

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
DON in Pediatric Cerebral Malaria: A Phase I/IIa Dose-Escalation Safety Study
Publikációk
A regiszteradat frissítve
2026. október 23.